- Fractyl Health, Inc. (NASDAQ: GUTS) shareholders should email fletcher@fmoorelaw.com
NEW YORK, Oct. 19, 2026 /PRNewswire/ —
What is the Investigation About?
On January 29, 2026, before the market opened, Fractyl Health, Inc. announced six-month data from its REMAIN-1 Midpoint Cohort evaluating Revita for weight maintenance after discontinuation of GLP-1 therapy. Revita-treated patients experienced 4.5% weight regain, compared with 7.5% in the sham-treatment group. The Company also stated that the cohort was not designed to be sufficiently powered for efficacy analysis. During an investor call that same day, management disclosed that one study site had higher-than-expected weight regain across both treatment groups and materially contributed to the results.
Following this news, the price of Fractyl stock fell $1.245 per share, or 68.03%, to close at $0.585 per share on January 29, 2026.
After the market closed that day, Canaccord Genuity reported that management attributed the variability at one site to a less robust diet and lifestyle counseling program. Morgan Stanley also downgraded Fractyl and reduced its price target from $8.00 to $2.00. The next day, Fractyl stock fell another $0.125 per share, or 21.37%, to close at $0.46 per share on January 30, 2026.
If you own Fractyl Health, Inc. (NASDAQ: GUTS) securities, please contact Fletcher Moore at fletcher@fmoorelaw.com.
You may be able to seek monetary damages, corporate governance reforms, reimbursement to the company, and a court approved incentive award at no cost to you whatsoever. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
MOORE LAW PLLC
30 Wall Street, 8th Floor
New York, NY 10005
fletcher@fmoorelaw.com
www.fmoorelaw.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-action-notice-moore-law-pllc-encourages-investors-in-fractyl-health-inc-to-contact-law-firm-302913147.html
SOURCE Moore Law PLLC
